Field evaluation of Biorespirim-T in young cattle: clinical, growth, and exploratory immune outcomes
Аннотация
Bovine respiratory disease is an important cause of morbidity, impaired growth, and antimicrobial use in young cattle, creating a need for complementary approaches that may support host defense under field conditions. We conducted a prospective controlled field evaluation of Biorespirim-T, a multicomponent hyperimmune biogenic preparation, in young cattle on a commercial farm in Kazakhstan. Clinical and production outcomes were evaluated in 80 animals (40 treated and 40 contemporaneous controls), while a separate exploratory longitudinal cohort of ten 1.5-year-old male cattle (five treated and five controls) was used to characterize selected cellular, phagocytic, and innate-defense indicators. Farm-recorded respiratory disease occurred in 5/40 treated calves and 11/40 controls (RR = 0.45, 95% CI 0.17–1.19; p = 0.161), while mortality was 0/40 and 2/40, respectively. Average daily gain was higher in treated animals (615 vs. 565 g/day; p = 0.0039; Hedges’ g = 0.77). Among affected calves, recorded treatment duration was shorter in the treated group (4.6 vs. 8.8 days; p < 0.001), although this post-enrollment subgroup outcome was interpreted cautiously. Exploratory immune profiling showed the largest between-group effect estimates for lysozyme activity and interferon-associated activity. Biorespirim-T administration was associated with higher average daily gain and several exploratory clinical and biological signals; however, the non-randomized design and small immunological cohort preclude causal inference and require confirmation in an adequately powered randomized field trial.